Essa Pharma Q1 2021 Earnings Report

ESSA Pharma reported financial results for the fiscal first quarter ended December 31, 2020.

Key Takeaways

ESSA Pharma reported having cash reserves and short-term investments of $74,500,856 as of December 31, 2020, reflecting the gross proceeds of the July 2020 financing of $48.9 million, less operating expenses in the intervening period.

Raised $48.9 million in an over-subscribed public offering.

FDA granted Fast Track Designation to EPI-7386.

Initiated a Phase 1 trial with EPI-7386 for patients with metastatic castration-resistant prostate cancer.

Announced a clinical collaboration with Janssen Research & Development, LLC to evaluate EPI-7386 in combination clinical trials with abiraterone acetate/prednisone or apalutamide.

EPS

-$0.2

Previous year: -$0.22